Hodges Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-15,592
| Closed | -$16K | – | 246 |
|
|
2019
Q1 | $16K | Hold |
15,592
| – | – | ﹤0.01% | 231 |
|
|
2018
Q4 | $12K | Hold |
15,592
| – | – | ﹤0.01% | 225 |
|
|
2018
Q3 | $33K | Hold |
15,592
| – | – | ﹤0.01% | 247 |
|
|
2018
Q2 | $36K | Hold |
15,592
| – | – | ﹤0.01% | 248 |
|
|
2018
Q1 | $50K | Hold |
15,592
| – | – | ﹤0.01% | 242 |
|
|
2017
Q4 | $64K | Sell |
15,592
-10,000
| -39% | -$43.5K | ﹤0.01% | 243 |
|
|
2017
Q3 | $116K | Buy |
25,592
+15,592
| +156% | +$63.2K | 0.01% | 246 |
|
|
2017
Q2 | $33K | Hold |
10,000
| – | – | ﹤0.01% | 258 |
|
|
2017
Q1 | $92K | Sell |
10,000
-15,000
| -60% | -$132K | ﹤0.01% | 260 |
|
|
2016
Q4 | $193K | Sell |
25,000
-10,000
| -29% | -$91.9K | 0.01% | 266 |
|
|
2016
Q3 | $400K | Hold |
35,000
| – | – | 0.02% | 219 |
|
|
2016
Q2 | $431K | Sell |
35,000
-20,000
| -36% | -$243K | 0.02% | 203 |
|
|
2016
Q1 | $556K | Buy |
55,000
+20,000
| +57% | +$235K | 0.03% | 196 |
|
|
2015
Q4 | $789K | Hold |
35,000
| – | – | 0.03% | 183 |
|
|
2015
Q3 | $581K | Buy |
35,000
+10,000
| +40% | +$200K | 0.02% | 204 |
|
|
2015
Q2 | $562K | Buy |
25,000
+5,000
| +25% | +$123K | 0.02% | 217 |
|
|
2015
Q1 | $516K | Buy |
20,000
+5,000
| +33% | +$127K | 0.02% | 212 |
|
|
2014
Q4 | $326K | Hold |
15,000
| – | – | 0.01% | 236 |
|
|
2014
Q3 | $284K | Hold |
15,000
| – | – | 0.01% | 245 |
|
|
2014
Q2 | $349K | Hold |
15,000
| – | – | 0.02% | 214 |
|
|
2014
Q1 | $505K | Hold |
15,000
| – | – | 0.03% | 180 |
|
|
2013
Q4 | $443K | Buy |
15,000
+3,000
| +25% | +$55K | 0.03% | 174 |
|
|
2013
Q3 | $184K | Buy |
+12,000
| New | +$222K | 0.02% | 217 |
|
Hodges Capital Management's OMED Position: Q2 2019 in Review
Hodges Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 15,592 shares — an estimated $16K sold.
Hodges Capital Management first reported a position in OMED in Q3 2013 and held it in 23 quarters. The position peaked at $789K in Q4 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Hodges Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Hodges Capital Management sold 15,592 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $16K.
- Hodges Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 23 quarters.
- Hodges Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $789K in Q4 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Hodges Capital Management's 13F filing for Q2 2019, filed 22 Aug 2019.